Navigation Links
Pioneering stem cell bandage receives approval for clinical trial
Date:6/4/2011

Millions of people with knee injuries could benefit from a new type of stem cell bandage treatment if clinical trials are successful. The world's first clinical trial for the treatment of patients with torn meniscal cartilage has received approval from the UK regulatory agency, the MHRA1, to commence.

The current treatment for the majority of tears is the removal of the meniscus, a procedure that often results in the early onset of osteoarthritis.

The Phase I trial, one of the first in the UK to be approved using stem cells, will treat meniscal tear patients with a cell bandage product, seeded with the patient's own, expanded, stem cells.

The cell bandage, produced by Azellon Ltd, a University of Bristol spin-out company, is focused on the research, development and commercialisation of an adult autologous (patient's own) stem cell technology which in vitro (tissue culture) has shown great promise for the healing of meniscal tears.

The trial is designed primarily to test the safety profile of Azellon's cell bandage in ten meniscal tear patients, but some information on whether or not it works will also be obtained. The bandage, containing the patient's own stem cells will be implanted in a simple surgical procedure using a specially designed instrument that helps to deliver the cells into the injured site as a first-line treatment in place of removal of the meniscus. Patients will be closely monitored for safety over a five-year follow-up period.

Professor Anthony Hollander, Chief Scientific Officer at Azellon Ltd and Head of the School of Cellular and Molecular Medicine at the University of Bristol, said: "The approval we have received from the MHRA is an important milestone in the development of stem cell therapies in the UK. These cells hold much scientific and medical promise but we can only know if they work or not by testing them out in clinical trials."

Professor Ashley Blom, Professor of Orthopaedic Surgery at the University of Bristol, added: "The effective repair of meniscal tears would represent a significant advance in treatment, particularly for younger patients and athletes by reducing the likelihood of early onset osteoarthritis, and would offer an exciting new treatment option for surgeons."

More than 900,000 patients have meniscal tears every year in Europe with perhaps 800,000 to one million meniscal repairs in US making the total market 1.7 million meniscal tears per year. Seven per cent of meniscal surgeries are repairs in the 'red' zone, the rest (1,581,000 tears) remain total or partial menisectomies. Meniscus tears normally occur in active and younger people (estimated 80 per cent of meniscal patients are younger than 50). Meniscus tear is a common sports injury and is especially prevalent amongst competitive athletes in football (including US and Australian rules), rugby and basketball. Patients who have partial or total menisectomy have an increased risk of developing osteoarthritis over the following 4.5 to eight years.


'/>"/>

Contact: Caroline Clancy
caroline.clancy@bristol.ac.uk
44-011-718-092
University of Bristol
Source:Eurekalert

Related medicine news :

1. Film director launches pioneering hearing research
2. Existence Genetics is Pioneering the Field of Predictive Medicine - Nexus Technologies Critical in Understanding and Preventing Deadly Disease
3. Dr. Alexander Rivkin's Pioneering Non-Surgical Nose and Eye Transformations Are Making Headlines and May Be Permanent Solutions
4. Pioneering treatment reduces disability in premature babies with serious brain hemorrhage
5. Voyant Health, Ltd. Announces the Launch of KingMark™, a Pioneering Calibration Marker that Calculates the Radiological Magnification of the Hip
6. Tony Blair Visits Pioneering Interfaith Malaria Initiative in Nigeria
7. Scripps Health Begins Pioneering Study of Human Tumor Sequencing in Cancer Patients
8. Pioneering Hormone Therapist to Host Free Health Seminar
9. UTMB researcher receives $3 million NIH grant to study aging in Mexico
10. UT Dallas Moller receives teaching award
11. Women & Infants receives support from CVS Caremark Charitable Trust
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... March 23, ... enables organizations to easily reprint customer invoices, bills, statements and other correspondence when ... the steps needed to retrieve and print the documents and batch them for ...
(Date:3/23/2017)... ... March 23, 2017 , ... Sharon Kleyne, host of the nationally syndicated ... Health on VoiceAmerica, recently talked on her program about how she is looking forward ... remind listeners of an important distinction. World Water Day, Kleyne pointed out, is an ...
(Date:3/23/2017)... ... March 23, 2017 , ... Corra Group ... at competitive pricing. Verisys through its FACIS and other services maintains ... Disciplinary actions. , “We are delighted to be able to offer these various ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... European Guidelines and the New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews ... http://www.fdanews.com/mdclineval                  , How will the new EU MDR language change the ...
(Date:3/23/2017)... ... ... “Wounded Woman Be Ye Healed-Passing On A Legacy”: a call to heal the wounded ... published author, Desiree M Webb, a registered nurse, minister of music, speaker, songwriter, recording ... her husband, Paul, for over twenty-nine years. Desiree enjoys writing, beach trips, ministering ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 2017  Ethicon* today announced the completion of ... held medical device company that manufactures and markets ... treatment of Gastroesophageal Reflux Disease (GERD). This acquisition ... portfolio of minimally invasive options for patients suffering ... of the transaction have not been disclosed. ...
(Date:3/23/2017)... , March 23, 2017  Additive Orthopaedics, ... announced that it has kicked off a multi-centered ... 3D printed bone segments. According to ... unique variable honeycomb lattice structures have already shown ... compared to current allograft wedges from which we ...
(Date:3/23/2017)... 23, 2017 Ascendis Pharma A/S (Nasdaq: ASND), ... to address significant unmet medical needs in rare diseases, ... call and webcast on Monday, April 3 during ENDO ... Orlando, Florida , to discuss new ... Growth Hormone, TransCon PTH and TransCon CNP). ...
Breaking Medicine Technology: